Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.

Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017 04 14; 38(15):1132-1143.

View in: PubMed

subject areas

Aged
Aminobutyrates
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Biphenyl Compounds
Blood Pressure
Chronic Disease
Death, Sudden, Cardiac
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Combinations
Drug Therapy, Combination
Enalapril
Female
Heart Failure
Hospitalization
Humans
Hypotension
Male
Neprilysin
Stroke Volume
Tetrazoles
Treatment Outcome
Valsartan

authors with profiles

Michael R. Zile